

# Intraarticular Morphine, Bupivacaine, and Morphine/ Bupivacaine for Pain Control after Knee Videarthroscopy

George F. Khoury, M.D.,\* Andrew C. N. Chen, Ph.D.,† Douglas E. Garland, M.D.,‡ Christoph Stein, M.D.§

Evidence has accumulated that opioids can produce potent antinociceptive effects by interacting with opioid receptors in peripheral tissues. This study sought to compare the effects of morphine with those of bupivacaine administered intraarticularly upon pain following arthroscopic knee surgery. In a double-blind, randomized manner, 33 patients received either morphine (1 mg in 20 ml NaCl; n = 11), bupivacaine (20 ml, 0.25%; n = 11), or a combination of the two (n = 11) intraarticularly at the completion of surgery. After 1, 2, 3, and 4 h and at the end of the 1st and 2nd postoperative days, pain was assessed by a visual analogue scale, and supplemental analgesic requirements were recorded. Pain scores were significantly greater in the morphine group than in the other two groups at 1 h. There were no significant differences at 2 and 3 h. From 4 h until the end of the study period, pain scores were significantly greater in the bupivacaine group than in the other two groups. Analgesic requirements were significantly greater in the morphine group than in the other groups at 1 h but were significantly greater in the bupivacaine group than in the other groups throughout the remainder of the study period. We conclude that intraarticular morphine produces an analgesic effect of delayed onset but of remarkably long duration. The combination of these two drugs results in satisfactory analgesia throughout the entire observation period. (Key words: Analgesics, opioid: morphine. Anesthetics, local: bupivacaine. Anesthetic techniques: intraarticular. Pain: postoperative.)

OPIOID ANALGESIA has been associated with activation of opioid receptors within the central nervous system. Evidence has also accumulated that exogenous<sup>1-3</sup> as well as endogenous<sup>4,5</sup> opioids can produce pronounced antinociceptive effects by interacting with opioid receptors in peripheral tissues. We have been able to differentiate the types of opioid receptors involved<sup>6</sup> and to demonstrate

such receptors on peripheral terminals of primary afferent neurons functionally<sup>7</sup> and *in situ*.<sup>5</sup> Furthermore, we have shown that peripherally administered opioids can elicit significant analgesic effects in humans.<sup>8,9</sup> Thus, low doses of intraarticular morphine, injected at the completion of arthroscopic knee surgery, can produce relatively long-lasting postoperative analgesia apparently *via* activation of local opioid receptors in the knee joint.<sup>9</sup>

Postoperative analgesia after arthroscopy has also been examined after the intraarticular administration of conventional local anesthetics.<sup>10,11</sup> So far, however, the results are equivocal. Thus, in patients receiving intraarticular bupivacaine, Henderson *et al.*<sup>10</sup> found no effect, whereas Chirwa *et al.*<sup>11</sup> found significantly reduced pain reports and supplemental analgesic use compared to controls.

The present study was designed 1) to examine the analgesic effect of intraarticular administration of a small dose of morphine upon postoperative pain in patients who had undergone arthroscopic knee surgery; 2) to compare the effect to that produced by a conventional local anesthetic, bupivacaine; and 3) to examine the effect of a combination of morphine and bupivacaine.

## Materials and Methods

### PATIENTS

The project was institutionally approved, and informed consent was obtained from each patient before surgery. Thirty-three outpatients undergoing arthroscopic knee surgery were studied. Surgical procedures included diagnostic tissue excisions, partial or total meniscectomies, and lateral release, with approximately equal representation among the groups. The criteria for exclusion from the study were ASA physical status rating of 3 and greater<sup>12</sup> and the requirement for postoperative intraarticular drainage. All patients received meperidine (1 mg/kg intramuscularly) and midazolam (0.03 mg/kg intramuscularly) 1 h before surgery. Anesthesia was induced with thiopental (4 mg/kg). Succinylcholine (1 mg/kg) was administered to facilitate tracheal intubation, after which anesthesia was maintained with O<sub>2</sub>/N<sub>2</sub>O and isoflurane (0.8-2.0%).

### EXPERIMENTAL DESIGN

At the conclusion of surgery but before the arthroscope was removed, patients received one of the following so-

\* Adjunct Associate Professor of Anesthesiology, Department of Anesthesiology, University of California, Los Angeles; Staff Anesthesiologist, Long Beach Community Hospital.

† Associate Professor of Pediatrics, Department of Pediatrics, University of California, Los Angeles.

‡ Clinical Professor of Orthopedics, Department of Orthopedic Surgery, University of Southern California, Los Angeles; Medical Staff, Long Beach Community Hospital.

§ Consultant of Anesthesiology, Department of Anesthesiology, Ludwig-Maximilians University, Klinikum Grosshadern, München; Department of Neuropharmacology, Max-Planck-Institut für Psychiatrie, Martinsried, Federal Republic of Germany.

Received from Long Beach Community Hospital, Long Beach, California. Accepted for publication April 16, 1992. Supported in part by the Deutsche Forschungsgemeinschaft (CS). Presented in part at the Annual Meeting of the Arthroscopy Association of North America, San Diego, California, April 1991 and at the Annual Meeting of the American Pain Society, New Orleans, Louisiana, November 1991.

Address reprint requests to Dr. Khoury: Department of Anesthesiology, UCLA School of Medicine, Los Angeles, California 90024-1778.

lutions intraarticularly in a double-blind, randomized manner: 1 mg morphine-sulfate in 20 ml NaCl ( $n = 11$ ), 20 ml 0.25% bupivacaine ( $n = 11$ ), or 1 mg morphine sulfate in 20 ml 0.25% bupivacaine ( $n = 11$ ). These doses were chosen based on previous animal and human studies.<sup>6,8,9,11</sup> Thereafter, general anesthesia was terminated. Since previous studies had shown that both intraarticular morphine and bupivacaine were more effective than saline,<sup>8,9,11,13</sup> we did not use such a control group, for ethical considerations.

#### PAIN ASSESSMENT

Postoperative pain was assessed using a 10-cm visual analogue scale (VAS)<sup>14</sup> ranging from "no pain" to "unbearable pain." Scores were taken at 1, 2, 3, and 4 h after drug injection and at the end of the 1st and 2nd postoperative days, respectively. Supplemental analgesic medication was available upon request and was recorded at the above intervals. In the recovery room, fentanyl was given in increments of 0.05 mg and titrated to the patient's subjective level of comfort. Upon discharge from the hospital, the patients were instructed to use 1 or 2 codeine tablets every 3 h, when needed, and were given a sheet of paper that had two VAS and a space for analgesics. They were asked to rate their pain intensity over the preceding 24 h and at the end of each postoperative day on the VAS and to record their analgesic usage at the same time. These sheets were then mailed back to the hospital by about 70% of the patients in each group.

#### DATA ANALYSIS

Demographic data were analyzed by analysis of variance (ANOVA).<sup>15</sup> To score the VAS, the distance (in millimeters) from the "no pain" end to the mark provided by the patient was measured. To determine supplemental analgesic requirements, meperidine doses were converted into codeine equivalents based on an equianalgesic ratio of 1:1.6.<sup>16</sup> Each patient's total consumption during their stay in the recovery room (1st h), in the outpatient department (2nd–4th h), and at home (1st and 2nd post-

operative days) was calculated. Comparisons of pain scores between groups were made using the Kruskal-Wallis test and Dunn's procedure for *post hoc* evaluation. Comparisons of analgesic consumption between groups were made using an ANOVA and Fisher's least significant difference (LSD) procedure for *post hoc* testing.<sup>15</sup> A  $P$  value  $\leq 0.05$  was considered significant.

#### Results

There were no significant differences (ANOVA) in patient demographics (table 1) and preoperative pain scores (average  $12.4 \pm 4$  mm).

VAS scores were not different between groups up to 3 h postoperatively ( $P > 0.05$ , Dunn's test) except for the 1st h, when the morphine group displayed significantly greater values than the other two groups ( $P < 0.006$ , Dunn's test). From the 4th postoperative hour until the end of the study period (2nd postoperative day), pain scores were significantly greater in the bupivacaine group than in the other two groups ( $P < 0.05$ , Dunn's test) (table 2).

Supplemental analgesic consumption was significantly greater in the bupivacaine group than in the other two groups throughout the study period ( $P < 0.05$ , LSD test) except for the 1st h, during which time the morphine group required significantly more than the other two groups ( $P < 0.001$ , LSD test) (table 3).

#### Discussion

In patients who have undergone arthroscopic knee surgery, intraarticular morphine produces more pronounced analgesia than intraarticular bupivacaine between the 4th h and the end of the 2nd postoperative day, whereas bupivacaine is a superior analgesic during the 1st h postinjection. The combination of both substances produces satisfactory analgesia throughout the entire study period.

The analgesic efficacy of these treatments is documented by a direct subjective measure of pain intensity, the VAS,<sup>14,17</sup> and an indirect indicator, supplemental analgesic requirements. Both measures appear to correlate well, in that during the 1st h both VAS scores and analgesic requirements were significantly greater in the group receiving morphine alone than in the other two groups, and between the 4th h and the end of the study period, both measures were greater in the group receiving bupivacaine alone than in the other two groups. Despite the larger amounts of requested additional analgesics, the respective differences in reported VAS scores remain quite distinct. These differences might have been even greater in the absence of additional medication, which, however, was impossible to withhold for obvious ethical reasons.

TABLE 1. Demographic Data

	Age (yr)	Weight (kg)	Duration of Surgery (min)
Morphine (n = 11)	44.0 $\pm$ 9.5	76.2 $\pm$ 2.7	67 $\pm$ 12
Bupivacaine (n = 11)	45.2 $\pm$ 8.0	74.3 $\pm$ 3.6	59 $\pm$ 7
Morphine + bupivacaine (n = 11)	44.9 $\pm$ 6.5	73.1 $\pm$ 2.2	61 $\pm$ 8

Means  $\pm$  SEM are given.

TABLE 2. Visual Analogue Scores

Time	1 h	2 h	3 h	4 h	1 day	2 days
Morphine (G1)	56.0 ± 10 24.15	28.3 ± 11 17.33	22.8 ± 7 12.33	13.9 ± 7 14.66	18.6 ± 6 12.72	13.9 ± 5 13.67
Bupivacaine (G2)	22.3 ± 9 12.18	26.5 ± 11 15.30	22.5 ± 6 16.95	32.8 ± 9 20.40	36.8 ± 7 21.23	28.6 ± 6 21.55
Morphine + bupivacaine	20.0 ± 4 13.86	14.3 ± 6 14.18	20.6 ± 5 16.77	8.6 ± 4 11.72	20.2 ± 3 13.46	13.0 ± 4 12.36
F value	10.07	0.74	1.74	5.71	5.76	6.67
P value	0.006	NS	NS	0.05	0.05	0.04
Post hoc Comparison	G1 > G2 G1 > G3			G2 > G1 G2 > G3	G2 > G1 G2 > G3	G2 > G1 G2 > G3

Means ± SEM (millimeters) and mean ranks are given. Data were analyzed by Kruskal-Wallis' and Dunn's procedures.

NS = difference not significant.

The present data suggest that intraarticular bupivacaine produces an immediate analgesic effect of relatively short duration, while morphine produces a much longer-lasting effect but with a delayed onset. These characteristics agree with previous reports examining the intraarticular administration of bupivacaine,<sup>10,11,18</sup> or morphine.<sup>8,9,18</sup>

To discuss these time courses of action, one has to consider several aspects. First, the question arises as to the site of action of these drugs. It is generally accepted that local anesthetics exert their effects through an action upon peripheral nerves, and the duration of action of bupivacaine observed here is entirely consistent with previous studies.<sup>11,13,19</sup> In the case of opioids, however, such effects have been demonstrated only recently. Thus, low doses of peripherally administered opioids can produce potent antinociceptive effects mediated by peripheral opioid receptors in inflamed tissue of the rat.<sup>3,6,20</sup> Moreover, in humans, low doses of intraarticular morphine can significantly inhibit postoperative pain by an activation of peripheral opioid receptors within the joint.<sup>9</sup> Similar to the spinal application of opioids, the duration of analgesia after intraarticular morphine appears to be considerably

longer than after systemic administration.<sup>21</sup> The remote possibility of a central action of this small dose of morphine, although not examined here, has been excluded in a previous study.<sup>9</sup> Other possible explanations are morphine's low lipid solubility<sup>21</sup> and its slow rate of absorption into the circulation resulting therefrom, or a relatively low blood flow to the articular area. In contrast, the relatively high lipophilicity of bupivacaine<sup>19</sup> could account for its faster uptake into the circulation and consequent removal from the joint. On the other hand, if one assumes sensory nerves to be the common site of action of these drugs (see below), these physicochemical characteristics could explain morphine's delayed and bupivacaine's immediate onset of action.

Second, the mechanisms of action of these drugs have to be taken into account. Local anesthetics are thought to produce their effects through inhibition of the generation and/or propagation of action potentials at the neuronal membrane and a resulting blockade of afferent nociceptive barrage.<sup>19</sup> In the case of opioids, two different peripheral mechanisms may result in a decreased nociception. On the one hand, morphine may diminish local posttraumatic inflammation through actions on leuko-

TABLE 3. Postoperative Analgesic Consumption

Time	Fentanyl (µg)	Codeine (mg)		
	1 h	2-4 h	Day 1	Day 2
Morphine (G1)	130.0 ± 16.7	45.0 ± 14.3	50.0 ± 21.0 (95.0 ± 14.5)	33.3 ± 21.6 (128.3 ± 13.9)
Bupivacaine (G2)	21.4 ± 6.4	105.0 ± 22.2	120.0 ± 26.6 (225.0 ± 23.9)	84.5 ± 23.2 (309.5 ± 21.2)
Morphine + bupivacaine (G3)	31.8 ± 10.1	36.0 ± 5.7	66.0 ± 11.8 (72.0 ± 6.6)	33.0 ± 6.6 (105.0 ± 5.8)
Value	24.54	5.73	2.92	6.51
Value	<0.001	0.008	0.049	0.005
Post hoc Comparison	G1 > G2 G1 > G3	G2 > G1 G2 > G3	G2 > G1 G2 > G3	G2 > G1 G2 > G3

The patients' total consumption during their stay in the recovery room (1 h), in the outpatient department (2-4 h), and at home (postoperative days 1 and 2) is given in means ± SEM. Data were analyzed

by analysis of variance and Fisher's least significant difference procedure. Cumulative amounts of codeine are given in brackets.

cytes,<sup>22,23</sup> inhibition of bradykinin formation,<sup>22</sup> or inhibition of plasma extravasation.<sup>24</sup> On the other hand, opioid binding sites have been shown on primary afferent neurons.<sup>25-27</sup> We have demonstrated such receptors functionally<sup>7</sup> and immunohistochemically.<sup>5</sup> Conceivably, activation of these neuronal receptors can cause attenuation of the excitability or nociceptive input terminals<sup>28-30</sup> and/or inhibition of release of excitatory transmitters<sup>31,32</sup> and ultimately result in antinociception.

In summary, we have shown that in patients having undergone arthroscopic surgery, intraarticular bupivacaine yields postoperative analgesia of immediate onset but only of short duration (2-3 h), whereas intraarticular morphine produces an analgesic effect of delayed onset (about 2 h postinjection), but of remarkably long duration (as long as 2 days postoperatively). The combination of these two drugs results in satisfactory analgesia throughout the entire observation period.

Mrs. G. Kahleis is gratefully acknowledged for preparing the manuscript.

### References

1. Ferreira SH, Nakamura M: Prostaglandin hyperalgesia: The peripheral analgesic activity of morphine, enkephalins and opioid antagonists. *Prostaglandins* 18:191-200, 1979
2. Smith TW, Buchan P, Parsons DN, Wilkinson S: Peripheral antinociceptive effects of N-methyl morphine. *Life Sci* 31:1205-1208, 1982
3. Stein C, Millan MJ, Shippenberg TS, Herz A: Peripheral effect of fentanyl upon nociception in inflamed tissue of the rat. *Neurosci Lett* 84:225-228, 1988
4. Stein C, Gramsch C, Herz A: Intrinsic mechanisms of antinociception in inflammation: Local opioid receptors and  $\beta$ -endorphin. *J Neurosci* 10:1292-1298, 1990
5. Stein C, Hassan AHS, Przewlocki R, Gramsch C, Peter K, Herz A: Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. *Proc Natl Acad Sci USA* 87:5935-5939, 1990
6. Stein C, Millan MJ, Shippenberg TS, Peter K, Herz A: Peripheral opioid receptors mediating antinociception in inflammation: Evidence for involvement of mu, delta and kappa receptors. *J Pharmacol Exp Ther* 248:1269-1275, 1989
7. Barthó L, Stein C, Herz A: Involvement of capsaicin-sensitive neurons in hyperalgesia and enhanced opioid antinociception in inflammation. *Haynyn Schmiedebergs Arch Pharmacol* 342: 666-670, 1990
8. Khoury GF, Stein C, Garland DE: Intra-articular morphine for pain after knee arthroscopy (letter). *Lancet* 336:871, 1990
9. Stein C, Comisel K, Haimerl F, Yassouridis A, Herz A, Peter K: Analgesic effect of intraarticular morphine after arthroscopic knee surgery. *N Engl J Med* 325:1123-1126, 1991
10. Henderson RC, Campion ER, DeMasi RA, Taft TN: Postarthroscopy analgesia with bupivacaine: A prospective, randomized, blinded evaluation. *Am J Sports Med* 18:614-617, 1990
11. Chirwa SS, MacLeod BA, Day B: Intraarticular bupivacaine (marchaine) after arthroscopic meniscectomy: A randomized double-blind controlled study. *Arthroscopy* 5:33-35, 1989
12. American Society of Anesthesiologists: Classification of Physical Status. *ANESTHESIOLOGY* 24:111, 1963
13. Kaeding CC, Hill JA, Katz J, Benson L: Bupivacaine use after knee arthroscopy: Pharmacokinetics and pain control study. *Arthroscopy* 6:33-39, 1990
14. Scott J, Huskisson EC: Graphic representation of pain. *Pain* 2: 175-184, 1976
15. Zar JH: *Biostatistical Analysis*, Englewood Cliffs, Prentice-Hall, 1984
16. Halpern LM: Analgesic drugs in the management of pain. *Arch Surg* 112:861-869, 1977
17. Chapman CB, Casey KL, Dubner R, Foley KM, Gracely RH, Reading AE: Pain measurement: An overview. *Pain* 22:1-31, 1985
18. Dickstein R, Raja SN, Johnson C: Comparison of intraarticular bupivacaine and morphine for analgesia following arthroscopic knee surgery. *ANESTHESIOLOGY* 75:A767, 1991
19. Strichartz GR, Covino BG: *Local anesthetics, Anesthesia*. 3rd ed. Edited by Miller RD. New York, Churchill Livingstone, 1990, pp 437-470
20. Joris JL, Dubner R, Haregreaves KM: Opioid analgesia at peripheral sites: A target for opioids released during stress and inflammation. *Anesth Analg* 66:1277-1281, 1987
21. Jaffe JH, Martin WR: *Opioid analgesics and antagonists: the pharmacological basis of therapeutics*, 8th edition. Edited by Gilman AG, Rall TW, Nies AS, Taylor P. New York, Pergamon Press, 1990, pp 485-521
22. Gyires K, Budavári I, Fürst S, Molnar I: Morphine inhibits the carrageenan-induced oedema and the chemoluminescence of leucocytes stimulated by zymosan. *J Pharm Pharmacol* 37:100-104, 1985
23. Wybran J: Enkephalins and endorphins as modifiers of the immune system: Present and future. *Fed Proc* 44:92-94, 1985
24. Barthó L, Szolcsányi J: Opiate agonists inhibit neurogenic plasma extravasation in the rat. *Eur J Pharmacol* 73:101-104, 1981
25. LaMotte C, Pert CB, Synder SH: Opiate receptor binding in primate spinal cord: Distribution and changes after dorsal root section. *Brain Res* 112:407-412, 1976
26. Fields HL, Emson PC, Leigh BK, Gilbert RFT, Iversen LL: Multiple opiate receptor sites on primary afferent fibres. *Nature* 284:351-353, 1980
27. Ninkovic M, Hunt SP, Gleave JRW: Localization of opiate and histamine H<sub>1</sub>-receptors in the primary sensory ganglia and spinal cord. *Brain Res* 241:197-206, 1982
28. Werz MA, Macdonald RL: Heterogeneous sensitivity of cultured dorsal root ganglion neurons to opioid peptides selective for  $\mu$ - and  $\delta$ -opiate receptors. *Nature* 299:730-733, 1982
29. Frank GB: Stereospecific opioid receptors on excitable cell membranes. *Can J Physiol Pharmacol* 63:1023-1032, 1985
30. Russell NJW, Schaible HG, Schmidt RF: Opiates inhibit the discharges of fine afferent units from inflamed knee joint of the cat. *Neurosci Lett* 76:107-112, 1987
31. Lembeck F, Donnerer J: Opioid control of the function of primary afferent substance P fibres. *Eur J Pharmacol* 114:241-246, 1985
32. Yaksh TL: Substance P release from knee joint afferent terminals: Modulation by opioids. *Brain Res* 458:319-324, 1988